BC, FAANP, explains how a fellowship program sets the tone for how to transition nurse practitioners to oncology.

Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

Panelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain ...

The FDA has granted accelerated approval to dordaviprone for use in adult and pediatric patients with H3 K27M-mutated diffuse midline glioma.

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient ...

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Cancer survivors, particularly men, in physically demanding jobs often face pressure to keep working during treatment, says ...

C, CNS, explained that understanding a patient’s emotional needs can help educate them on treatment adherence.

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in ...

Panelists emphasize the importance of multidisciplinary collaboration, patient education, and advocacy in managing multiple ...

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T-cell engagers, ...

Panelists discuss City of Hope’s collaborative partnership with community physicians, emphasizing expert evaluation at ...